SylvainGarciaz Institut Paoli-CalmettesFrance

SylvainGarciaz
Dr. Sylvain Garciaz is a physician-scientist specializing in hematology. He did his medical school at Marseille University in France and his Ph.D. at the Marseille Cancer Research Center focusing on AML resistance to therapeutics. In 2019, he was awarded a post-doctoral fellowship in the Mark Dawson’s Lab at PeterMac Callum Cancer Centre in Melbourne. His scientific work focuses on resistance to BH3 mimetics in acute myeloid leukemia and new therapeutics. From 2019 to the present, he is an Associate Professor at Paoli-Calmettes Institute in Marseille, Coordinator of the Labeled Early Phase Trials Center ( CLIP²).

Wednesday 10 June 2026

Time Session
08:30
09:15
TP53 mutations are common in AML, often as “multi-hit” types linked to complex karyotypes. Using single-cell DNA sequencing and phenotypic analysis, we examined the zygosity and clonal architecture of TP53m AML. Among eight patients, “multi-hit” TP53 anomalies appeared in blast cells but not in mature lymphoid populations. Minor TP53m heterozygous clones persisted in mature cells and at remission, with dominant “multi-hit” clones resurfacing at relapse. The combined scDNAseq and CITEseq approach highlights distinct mutation patterns, aiding therapy guidance by distinguishing pathological multi-hit mutations from clonal haematopoiesis at remission.
JenniferStobbs Industry Moderator/ Chair Mission BioUnited States
Room F6+7+8